The oral, selective KRAS G12C inhibitor The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
KRAS-G12C mutations occur in approximately 14% of patients with NSCLC. The KRYSTAL-1 study, a multi-cohort Phase 1/2 trial, evaluated adagrasib as a monotherapy or in combination for patients with KRAS-G12C-mutated solid tumors. The U.S. Food and Drug Administration already granted accelerated approval of adagrasib for patients with previously treated KRAS-G12C-mutated advanced/metastatic NSCLC based on data from this study.
In the two-year follow-up, pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A, 132 patients with KRAS-G12C-mutated NSCLC were treated with adagrasib 600 mg orally twice daily. The median age of patients was 64 years, with 56.8% being female. At baseline, 19.7% of patients had central nervous system metastases. Patients had received a median of two prior therapies, including platinum-based and checkpoint inhibitor therapies.
According to Shirish Gadgeel, MD from Henry Ford Cancer Institute, Henry Ford Health System, in Detroit, Mich., the results showed a favorable objective response rate of 43.0%, with a median duration of response of 12.4 months. The median progression-free survival was 6.9 months, and the median overall survival was 14.1 months. Notably, 52.8% of patients were still alive at one year, and approximately one in three patients remained alive at two years.
The study data demonstrates promising results, providing hope for patients with this specific mutation. Exploratory analyses indicated that the presence of co-mutations, such as KEAP1, STK11, or TP53, may impact the clinical benefit of adagrasib and warrant further investigation." Related StoriesDr. Gadgeel reported that treatment-related adverse events were manageable, with grade ≥3 TRAEs occurring in 40.9% of patients. Only 2.
The ongoing Phase 3 trial evaluating adagrasib monotherapy compared with docetaxel in previously treated advanced KRAS-G12C-mutated NSCLC holds great promise and could further establish adagrasib as an essential treatment option for patients with this specific mutation, he reported.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutationsThe oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Læs mere »
Color of phlegm can predict outcomes for patients with the lung disease, bronchiectasisThe color of the phlegm from patients with the lung disease bronchiectasis can indicate the degree of inflammation in their lungs and predict their future outcomes, according to new research presented at the European Respiratory Society International Congress in Milan, Italy.
Læs mere »
Unlocking the genetic code of blood sugar reveals new diabetes risks and lung complicationsThe study used a genome-wide association study (GWAS) to analyze random glucose levels in nearly half a million non-diabetic subjects, uncovering 150 distinct genetic signals, including 53 new ones, linked to glycemic traits and type 2 diabetes. The research also discovered a causal effect of random glucose and type 2 diabetes on lung function, identifying lung dysfunction as a new diabetes complication.
Læs mere »
Color of the phlegm can indicate degree of lung inflammation in patients with bronchiectasisThe color of the phlegm from patients with the lung disease bronchiectasis can indicate the degree of inflammation in their lungs and predict their future outcomes, according to new research presented at the European Respiratory Society International Congress in Milan, Italy.
Læs mere »
Stigmatization of smoking-related diseases is a barrier to care, and the problem may be on the riseThe stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Læs mere »
Six-year follow-up data on survival, benefits for patients with metastatic NSCLC and nivolumab + ipilimumab treatmentResearch findings from the CheckMate 227 trial will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore, shedding light on the six-year survival and quality of life benefits associated with first-line nivolumab + ipilimumab therapy.
Læs mere »